A detailed history of Mackenzie Financial Corp transactions in Cerus Corp stock. As of the latest transaction made, Mackenzie Financial Corp holds 11,361 shares of CERS stock, worth $17,950. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,361
Previous 11,361 -0.0%
Holding current value
$17,950
Previous $19,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$3.38 - $4.22 $226,051 - $282,229
-66,879 Reduced 85.48%
11,361 $41,000
Q3 2022

Oct 07, 2022

SELL
$3.43 - $5.83 $1,317 - $2,238
-384 Reduced 0.49%
78,240 $282,000
Q2 2022

Aug 10, 2022

BUY
$4.41 - $5.69 $9,984 - $12,882
2,264 Added 2.96%
78,624 $416,000
Q1 2022

May 13, 2022

SELL
$4.81 - $6.99 $43,872 - $63,755
-9,121 Reduced 10.67%
76,360 $419,000
Q4 2021

Feb 14, 2022

SELL
$5.97 - $7.93 $4,244 - $5,638
-711 Reduced 0.82%
85,481 $582,000
Q3 2021

Nov 08, 2021

BUY
$4.79 - $6.68 $19,773 - $27,575
4,128 Added 5.03%
86,192 $525,000
Q2 2021

Aug 11, 2021

BUY
$5.35 - $6.35 $73,969 - $87,795
13,826 Added 20.26%
82,064 $485,000
Q1 2021

May 14, 2021

BUY
$5.68 - $7.87 $9,996 - $13,851
1,760 Added 2.65%
68,238 $410,000
Q4 2020

Feb 10, 2021

SELL
$5.25 - $8.56 $306,285 - $499,390
-58,340 Reduced 46.74%
66,478 $460,000
Q3 2020

Nov 13, 2020

BUY
$5.78 - $7.47 $231,205 - $298,807
40,001 Added 47.16%
124,818 $781,000
Q2 2020

Aug 13, 2020

BUY
$4.5 - $7.02 $34,285 - $53,485
7,619 Added 9.87%
84,817 $559,000
Q1 2020

May 14, 2020

BUY
$2.87 - $5.49 $221,558 - $423,817
77,198 New
77,198 $358,000
Q1 2019

May 15, 2019

SELL
$5.16 - $6.85 $87,720 - $116,450
-17,000 Closed
0 $0
Q4 2018

Feb 06, 2019

BUY
$4.89 - $7.16 $2,445 - $3,580
500 Added 3.03%
17,000 $86,000
Q3 2018

Nov 15, 2018

BUY
$6.89 - $7.78 $113,685 - $128,370
16,500 New
16,500 $119,000

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $280M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Mackenzie Financial Corp Portfolio

Follow Mackenzie Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.